Canada - English - Health Canada

alveda pharmaceuticals inc - ephedrine sulfate - liquid - 50mg - ephedrine sulfate 50mg - alpha-and beta-adrenergic agonists

United States - English - NLM (National Library of Medicine)

cantrell drug company - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 10 mg in 1 ml

United States - English - NLM (National Library of Medicine)

andersen pharma llc - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 50 mg in 1 ml

United States - English - NLM (National Library of Medicine)

aurohealth llc - pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - pseudoephedrine hydrochloride 120 mg - nasal decongestant - temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies - temporarily relieves sinus congestion and pressure if you are now taking a prescription monoamine oxidase inhibitor (maoi) (certain drugs for depression, psychiatric or emotional conditions, or parkinson’s disease), or for 2 weeks after stopping the maoi drug. if you do not know if your prescription drug contains an maoi, ask a doctor or pharmacist before taking this product. - heart disease - high blood pressure - thyroid disease - diabetes - trouble urinating due to an enlarged prostate gland -  nervousness, dizziness, or sleeplessness occur - symptoms do not improve within 7 days or occur with a fever

United States - English - NLM (National Library of Medicine)

chain drug consortium, llc - pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - pseudoephedrine hydrochloride 120 mg - nasal decongestant - temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies - temporarily relieves sinus congestion and pressure

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; sodium chloride; dilute hydrochloric acid; sodium hydroxide; sodium citrate - treatment of hypotension secondary to spinal anaesthesia

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: citric acid monohydrate; dilute hydrochloric acid; water for injections; sodium hydroxide; sodium chloride; sodium citrate - treatment of hypotension secondary to spinal anaesthesia

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ephedrine sulfate, quantity: 30 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - ephedrine is indicated in the treatment of shock unresponsive to fluid replacement. it is also indicated in the treatment of hypotension secondary to spinal anaesthesia. ephedrine sulfate injection has also been used in the treatment of bronchial asthma and reversible bronchospasm although more selective agents (beta adrenergic agonists) are now available.

United States - English - NLM (National Library of Medicine)

akorn - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary limited published data on the use of ephedrine sulfate are insufficient to determine a drug associated risk of major birth defects or miscarriage. however, there are clinical considerations [see clinical considerations ]. animal reproduction studies have not been conducted with ephedrine sulfate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations fetal/neonatal adverse reactions cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. these

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none r isk summary limited published data on the use of ephedrine sulfate are insufficient to determine a drug associated risk of major birth defects or miscarriage. however, there are clinical considerations [see clinical considerations] . animal reproduction studies have not been conducted with ephedrine sulfate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown.  all pregnancies have a background risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. c linical considerations fetal/neonatal adverse reactions cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. th